Artiva Biotherapeutics

Name

Artiva Biotherapeutics

Legal name

Artiva Biotherapeutics, Inc.

Website

https://artivabio.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Allogeneic NK Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Allogeneic cell therapy
• Natural killer cell therapy
• Autoimmune disease therapy
• Cell-based immunotherapy
• Cryopreserved cell products

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. AlloNK Therapeutic Revenue: Artiva is a clinical-stage biopharmaceutical company with no current revenue. The company is developing AlloNK for autoimmune diseases with a planned Phase 3 registrational trial in refractory rheumatoid arthritis (initiating 2026) and anticipated BLA submission in 2029. Cantor Fitzgerald projects a path to over $1 billion in annual revenue if approved.
2. None - Pre-Revenue Stage: Artiva reported $0 revenue in FY2025 with a net loss of $83.9 million. The company is in clinical development stage with no commercialized products.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell-based therapies. Its lead product candidate, AlloNK (AB-101), is a non-genetically modified, cryopreserved NK cell therapy intended to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with B-cell targeted monoclonal antibodies (rituximab, obinutuzumab) to drive deep B-cell depletion in autoimmune diseases. The pipeline also includes CAR-NK candidates AB-205 (CD5-directed) and AB-201 (HER2-directed).

Product overview

Artiva Biotherapeutics is a clinical-stage biotechnology company developing a portfolio of allogeneic natural killer (NK) cell-based therapies. The core product is AlloNK® (AB-101), a non-genetically modified, cryopreserved NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with B-cell targeted monoclonal antibodies like rituximab or obinutuzumab. The company operates under a 'manufacturing-first' approach, leveraging a partnership with GC Cell Corporation for scalable production. Pipeline includes CAR-NK programs AB-205 (CD5-directed for hematologic malignancies) and AB-201 (HER2-directed for solid tumors). Current clinical focus is on autoimmune diseases including rheumatoid arthritis, Sjögren's disease, systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.

Differentiator

Problem solved

Functional benefit

Brands

• AlloNK: Non-genetically modified, cryopreserved NK cell therapy candidate being evaluated in combination with B-cell targeted monoclonal antibodies for autoimmune diseases. Also known as AB-101.
• AB-101
• AB-205
• AB-201

Products and services

• AlloNK (AB-101)
• AB-205 (CD5-Directed CAR-NK)
• AB-201 (HER2 CAR-NK)

Quantifiable outcome

• 71% of refractory RA patients achieved ACR50 response at six months in Phase 2a trial (21 patients)
• +4 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered major and core.

• IRIS (Investigator-Initiated Trial Partner)majorStrategic or Co-development Partner · 1 April 2024IRIS, a large community practice rheumatology clinic in Florida, submitted an IND to FDA for a basket investigator-initiated trial (NCT06581562) assessing AlloNK in combination with rituximab for RA, pemphigus vulgaris, SLE, and ANCA-associated vasculitis (GPA/MPA).
• GC Cell CorporationcoreStrategic or Co-development PartnerStrategic manufacturing partner providing access to state-of-the-art cell therapy research and cGMP manufacturing facilities in Seoul, Korea. GC Cell is a subsidiary of GC Holdings. The partnership leverages over a decade's work by GC Cell in NK cell expansion technology. GC Cell holds ex-APAC rights to all Artiva programs. Total rights to programs held by Artiva ex-APAC.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Adaptimmune Therapeutics: Adaptimmune is developing engineered T-cell therapies (SPEAR T-cells) for solid tumors with a recently approved product. Adjacent cell therapy space with overlapping manufacturing and regulatory know-how though autologous rather than allogeneic.
• Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with multiple clinical-stage oncology programs. Less direct overlap given oncology focus, but shares the allogeneic off-the-shelf cell therapy platform approach and manufacturing infrastructure.
• Vertex Pharmaceuticals (VX-880/ImmunoQure/ Alpine acquisition): Vertex is developing cell therapies for type 1 diabetes and other indications, and through Alpine Immune Sciences has lupus nephritis programs. Large-cap incumbent with growing autoimmune cell therapy footprint that competes for share of voice in autoimmune space.

Emerging players

• Century Therapeutics: Century is developing iPSC-derived allogeneic cell therapies including NK and T cell programs. Comparable platform-level technology with similar off-the-shelf manufacturing ambition though earlier-stage clinical pipeline.
• Senti Biosciences: Senti Biosciences is developing gene circuit-engineered cell therapies including NK cell programs. Emerging player with comparable cell engineering approach though primarily oncology-focused.
• Caribou Biosciences: Caribou is developing allogeneic CAR-T and CAR-NK cell therapies using CRISPR-based genome editing. Comparable allogeneic platform technology, though primarily focused on hematologic malignancies with emerging autoimmune interest.

Direct peers

• Kyverna Therapeutics: Kyverna is developing CAR-T cell therapies (CD19) for autoimmune diseases including lupus nephritis, myositis, and MS. Competing head-to-head with Artiva in B-cell driven autoimmune indications using autologous CAR-T rather than allogeneic NK cells.
• Fate Therapeutics: Fate Therapeutics is a clinical-stage company developing off-the-shelf, iPSC-derived NK cell and T-cell therapies, including programs for autoimmune disease. Directly comparable to Artiva as both pursue allogeneic NK cell platforms with similar target indications and off-the-shelf manufacturing.
• Cabaletta Bio: Cabaletta Bio is developing CAR-T cell therapies (CD19, CD20) for autoimmune diseases including lupus, myositis, and RA. Direct competitor pursuing deep B-cell depletion in the same indications via a different cell therapy modality (T cells vs NK cells).
• Nkarta Therapeutics: Nkarta is developing allogeneic NK cell therapies engineered with CARs and membrane-bound IL-15 for autoimmune and oncology indications. Most directly comparable peer given overlapping NK cell approach, autoimmune focus, and allogeneic off-the-shelf model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/artivabio
• LinkedInlinkedin.com/company/artiva-biotherapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artiva Biotherapeutics